Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lymph Node Ratio is More Predictive than Traditional Lymph Node Stratification in Lymph Node Positive Invasive Breast Cancer

  • Bai, Lian-Song (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University) ;
  • Chen, Chuang (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University) ;
  • Gong, Yi-Ping (Department of Breast Surgery, Hubei Cancer Hospital) ;
  • Wei, Wen (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University) ;
  • Tu, Yi (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University) ;
  • Yao, Feng (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University) ;
  • Li, Juan-Juan (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University) ;
  • Wang, Li-Jun (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University) ;
  • Sun, Sheng-Rong (Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the relationships between lymph node ratio (LNR, the ratio of positive lymph nodes in excised axillary lymph nodes) and disease-free survival (DFS) by comparing with traditional absolute positive lymph node number (pN classification) for prediction of breast cancer (BC) progrnosis. Methods and Patients: We retrospectively reviewed patients who received comprehensive therapy in Department of Breast Surgery, Hubei Cancer Hospital, China from Jan 2002 to Dec 2006 (Group A), and Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, China from Jun 2008 to May 2012 (Group B). Patients were allocated to low-risk (${\leq}0.20$), intermediate-risk (> 0.20 but ${\leq}0.65$), high-risk (>0.65) groups by LNR. The primary endpoint was 5-DFS. Results: A total of 294 patients were included in our study. LNR was verified as a negative prognostic factor for DFS (P=0.002 in Group A, P<0.0001 in Group B). Then we found the effects of pN and LNR delamination on disease-free survival (DFS) had statistical significance (P=0.012 for pN and P=0.031 for LNR stratification in Group A, both of them P<0.001 in Group B). Compared to pN staging, LNR staging displayed superior performance in prognosis, the adjusted hazard ratio of recurrence being 2.07 (95%CI, 1.07 to 4.0) for intermediate risk group (P=0.030) and 2.44 (95%CI, 1.21 to 4.92) for high risk group (P=0.013) in Group A. Conclusions: LNR stratification proved an adverse prognostic factor of DFS in lymph nodes positive invasive BC using cut-off values 0.20 and 0.65, and was more predictive than traditional pN classification for 5-DFS.

Keywords

References

  1. Chen C, Xia HS, Gong YP, et al (2010). The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials, 31, 8818-25. https://doi.org/10.1016/j.biomaterials.2010.07.091
  2. Cianfrocca M, Gradishar W (2009). New molecular classifications of breast cancer. CA Cancer J Clin, 59, 303-13. https://doi.org/10.3322/caac.20029
  3. Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA Jr (2010). Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. J Am Coll Surg, 210, 797-805.e1, 805-7. https://doi.org/10.1016/j.jamcollsurg.2010.02.045
  4. der Wal BC v, Butzelaar RM, der Meij S v, Boermeester MA (2002). Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol, 28, 481-9. https://doi.org/10.1053/ejso.2002.1239
  5. Duraker N, Bati B, Demir D, Caynak ZC (2011). Prognostic significance of the number of removed and metastatic lymph nodes and lymph node ratio in breast carcinoma patients with 1-3 axillary lymph node(s) metastasis. ISRN Oncol, 2011, 645450.
  6. Fan L, Zheng Y, Yu KD, et al (2009). Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat, 117, 409-16. https://doi.org/10.1007/s10549-008-0303-z
  7. Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29. https://doi.org/10.1093/annonc/mdp322
  8. Han TJ, Kang EY, Jeon W, et al (2011). The prognostic value of the nodal ratio in N1 breast cancer. Radiat Oncol, 6, 131. https://doi.org/10.1186/1748-717X-6-131
  9. Harper S, Lynch J, Meersman SC, et al (2009). Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev, 18, 121-31. https://doi.org/10.1158/1055-9965.EPI-08-0679
  10. Hatoum HA, Jamali FR, El-Saghir NS, et al (2009). Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol, 16, 3388-95. https://doi.org/10.1245/s10434-009-0653-8
  11. Ibrahim EM, Elkhodary TR, Zekri JM, et al (2010). Prognostic value of lymph node ratio in poor prognosis node-positive breast cancer patients in Saudi Arabia. Asia Pac J Clin Oncol, 6, 130-7. https://doi.org/10.1111/j.1743-7563.2010.01288.x
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  14. Karihtala P, Winqvist R, Bloigu R, Jukkola-Vuorinen A (2010). Long-term observational follow-up study of breast cancer diagnosed in women https://doi.org/10.1016/j.breast.2010.05.001
  15. Kim JY, Ryu MR, Choi BO, et al. (2011).The prognostic significance of the lymph node ratio in axillary lymph node positive breast cancer. J Breast Cancer, 14, 204-12. https://doi.org/10.4048/jbc.2011.14.3.204
  16. Mersin H, Yildirim E, Berberoglu U, Gulben K (2009). Triple negative phenotype and N-ratio are important for prognosis in patients with stage IIIB non-inflammatory breast carcinoma. J Surg Oncol, 100, 681-7. https://doi.org/10.1002/jso.21411
  17. Overman MJ, Hu CY, Wolff RA, Chang GJ (2010). Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer, 116, 5374-82. https://doi.org/10.1002/cncr.25324
  18. Pedraza AM, Pollan M, Pastor-Barriuso R, Cabanes A (2012). Disparities in breast cancer mortality trends in a middle income country. Breast Cancer Res Treat, 134, 1199-207. https://doi.org/10.1007/s10549-012-2026-4
  19. Schiffman SC, McMasters KM, Scoggins CR, Martin RC, Chagpar AB (2011). Lymph node ratio: a proposed refinement of current axillary staging in breast cancer patients. J Am Coll Surg, 213, 45-52; discussion 52-3. https://doi.org/10.1016/j.jamcollsurg.2011.04.024
  20. Schmoor C, Sauerbrei W, Bastert G, Bojar H, Schumacher M (2001). Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. Eur J Cancer, 37, 1123-31. https://doi.org/10.1016/S0959-8049(01)00090-9
  21. Schootman M, Lian M, Deshpande AD, et al (2010). Temporal trends in area socioeconomic disparities in breast-cancer incidence and mortality, 1988-2005. Breast Cancer Res Treat, 122, 533-43. https://doi.org/10.1007/s10549-009-0729-y
  22. Singletary SE, Allred C, Ashley P, et al (2002). Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol, 20, 3628-36. https://doi.org/10.1200/JCO.2002.02.026
  23. Singletary SE, Connolly JL (2006). Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin, 56, 37-47; quiz 50-1. https://doi.org/10.3322/canjclin.56.1.37
  24. Sotiriou C, Pusztai L (2009). Gene-expression signatures in breast cancer. N Engl J Med, 360, 790-800. https://doi.org/10.1056/NEJMra0801289
  25. Tausch C, Taucher S, Dubsky P, et al (2012). Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol, 19, 1808-17. https://doi.org/10.1245/s10434-011-2189-y
  26. Truong PT, Berthelet E, Lee J, Kader HA, Olivotto IA (2005). The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer, 103, 2006-14. https://doi.org/10.1002/cncr.20969
  27. Veronesi U, Zurrida S, Viale G, et al (2009). Rethinking TNM: a breast cancer classification to guide to treatment and facilitate research. Breast J, 15, 291-5. https://doi.org/10.1111/j.1524-4741.2009.00719.x
  28. Vinh-Hung V, Joseph SA, Coutty N, et al (2010). Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer. Oncologis, 15, 1050-62. https://doi.org/10.1634/theoncologist.2010-0044
  29. Vinh-Hung V, Verkooijen HM, Fioretta G, et al (2009). Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol, 27, 1062-8. https://doi.org/10.1200/JCO.2008.18.6965
  30. Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G (2004). The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol, 70, 225-30. https://doi.org/10.1016/j.radonc.2003.10.015
  31. Weigelt B, Baehner FL, Reis-Filho JS (2010). The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol, 220, 263-80.

Cited by

  1. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio vol.21, pp.5, 2016, https://doi.org/10.1007/s10147-016-0956-2
  2. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy pp.1573-7217, 2018, https://doi.org/10.1007/s10549-018-4966-9